[go: up one dir, main page]

WO2024252184A3 - Anti-cldn18_2 antibody and an in vitro diagnostic kit - Google Patents

Anti-cldn18_2 antibody and an in vitro diagnostic kit Download PDF

Info

Publication number
WO2024252184A3
WO2024252184A3 PCT/IB2024/000278 IB2024000278W WO2024252184A3 WO 2024252184 A3 WO2024252184 A3 WO 2024252184A3 IB 2024000278 W IB2024000278 W IB 2024000278W WO 2024252184 A3 WO2024252184 A3 WO 2024252184A3
Authority
WO
WIPO (PCT)
Prior art keywords
antibody
cldn18
diagnostic kit
vitro diagnostic
claudin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/IB2024/000278
Other languages
French (fr)
Other versions
WO2024252184A2 (en
Inventor
Yong Wen
Guwei HOU
Song FU
Jiye SUN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Aosaikang Biopharmaceutical Co Ltd
Original Assignee
Jiangsu Aosaikang Biopharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Aosaikang Biopharmaceutical Co Ltd filed Critical Jiangsu Aosaikang Biopharmaceutical Co Ltd
Priority to CN202480026772.4A priority Critical patent/CN121039161A/en
Publication of WO2024252184A2 publication Critical patent/WO2024252184A2/en
Publication of WO2024252184A3 publication Critical patent/WO2024252184A3/en
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57446—Specifically defined cancers of stomach or intestine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present disclosure relates to kits comprising an anti claudin 18.2 antibody that are useful for assessing expression claudin 18.2 expression in a biological sample obtained from a human, e.g., a human patient having cancer.
PCT/IB2024/000278 2023-06-07 2024-06-07 Anti-cldn18_2 antibody and an in vitro diagnostic kit Pending WO2024252184A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480026772.4A CN121039161A (en) 2023-06-07 2024-06-07 Anti-cldn18_2 antibody and in vitro diagnostic kit thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202310675165.8 2023-06-07
CN202310675165.8A CN119101162A (en) 2023-06-07 2023-06-07 An anti-CLDN18_2 antibody and in vitro diagnostic kit

Publications (2)

Publication Number Publication Date
WO2024252184A2 WO2024252184A2 (en) 2024-12-12
WO2024252184A3 true WO2024252184A3 (en) 2025-02-06

Family

ID=91753800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2024/000278 Pending WO2024252184A2 (en) 2023-06-07 2024-06-07 Anti-cldn18_2 antibody and an in vitro diagnostic kit

Country Status (2)

Country Link
CN (3) CN119101162A (en)
WO (1) WO2024252184A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517447A (en) * 2013-03-18 2016-06-16 ガニメド ファーマシューティカルズ アーゲー Therapies comprising antibodies against claudin 18.2 for the treatment of cancer
CN110174363A (en) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
WO2019174617A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
WO2022032003A2 (en) * 2020-08-06 2022-02-10 Abpro Corporation Anti-claudin 18.2 antibodies and uses thereof
US20230096452A1 (en) * 2020-02-10 2023-03-30 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016517447A (en) * 2013-03-18 2016-06-16 ガニメド ファーマシューティカルズ アーゲー Therapies comprising antibodies against claudin 18.2 for the treatment of cancer
WO2019174617A1 (en) * 2018-03-14 2019-09-19 Beijing Xuanyi Pharmasciences Co., Ltd. Anti-claudin 18.2 antibodies
CN110174363A (en) * 2019-01-09 2019-08-27 北京九强生物技术股份有限公司 Glucose-6-phosphate dehydrogenase mutant and its purposes in preparation detection reagent
US20230096452A1 (en) * 2020-02-10 2023-03-30 Shanghai Escugen Biotechnology Co., Ltd. Claudin 18.2 antibody and use thereof
WO2022032003A2 (en) * 2020-08-06 2022-02-10 Abpro Corporation Anti-claudin 18.2 antibodies and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ZHANG MIAO ET AL: "A phase I/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors.", JOURNAL OF CLINICAL ONCOLOGY, vol. 41, no. 4_suppl, 1 February 2023 (2023-02-01), pages 397 - 397, XP093228766, ISSN: 0732-183X, DOI: 10.1200/JCO.2023.41.4_suppl.397 *

Also Published As

Publication number Publication date
CN119101162A (en) 2024-12-10
CN118307678A (en) 2024-07-09
WO2024252184A2 (en) 2024-12-12
CN121039161A (en) 2025-11-28

Similar Documents

Publication Publication Date Title
CY1122210T1 (en) HUMAN ANTI-SOD1 ANTIBODIES
EP2667194A3 (en) Ratio based biomarkers and methods of use thereof
EP2650308A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EP2586795A3 (en) Use of anti-amyloid beta antibody in ocular diseases
EP2485047A3 (en) Methods and marker combinations for screening for predisposition to lung cancer
WO2006127861A3 (en) Diagnosis of diseases and conditions by analysis of histopathologically processed biological samples using liquid tissue preparations
Podgaec et al. Foxp3 expression in deep rectosigmoid endometriosis lesions and its association with chronic pelvic pain
WO2022026360A3 (en) Monoclonal antibodies against lilrb1 for diagnostic and therapeutic use
WO2024252184A3 (en) Anti-cldn18_2 antibody and an in vitro diagnostic kit
WO2020041360A8 (en) Dbpa antibodies and uses thereof
WO2023169896A8 (en) BINDING MOLECULES AGAINST FRα
WO2021202542A3 (en) Methods of profiling translation rate
MX2023005346A (en) Anti-tspan8-anti-cd3 bispecific antibody and anti-tspan8 antibody.
WO2023205180A9 (en) Biomarkers for cbl, and compositions and methods for their use
WO2020180147A3 (en) Composite marker for diagnosis of age related macular degeneration and use thereof
ES8501630A1 (en) In vitro diagnostic methods using monoclonal antibodies against connective tissue proteins.
WO2023152568A3 (en) Compositions and methods for characterizing lung cancer by means of cell free rna
MX2025007872A (en) Anti-il-18bp antibodies
WO2006094014A3 (en) Methods for diagnosis and treatment of endometrial cancer
WO2022082030A3 (en) Antigen-binding proteins and related methods of use
EP2527358A3 (en) Diagnostic assay
AU2011291450A8 (en) TAM receptors and TAM receptor ligands in detection and modulation of neuropathological disease
EP4123304A4 (en) Nanowell diagnostic kit for diagnosing cardiovascular disease substances in blood
WO2021079002A8 (en) Novel anti-nogo-a antibodies
NZ581416A (en) Antibodies useful for therapy and diagnosis of melanoma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24754761

Country of ref document: EP

Kind code of ref document: A2